Replication data for: The Effects of Pharmaceutical Marketing and Promotion on Adverse Drug Events and Regulation

This paper analyzes the relationship between postmarketing promotional activity and reporting of adverse drug reactions (ADRs) by modeling the interaction between a regulator (the FDA) and a pharmaceutical firm. Promotion-driven market expansions enhance profitability yet may involve the risk of inappropriate drug prescriptions, leading to regulatory actions against the firm. We empirically test the relationship between drug promotion and reporting of ADRs using an innovative combination of commercial data on pharmaceutical promotion and FDA data on regulatory interventions and ADRs. We provide some evidence that increased levels of promotion and advertising lead to increased reporting of ADRs for certain conditions. (JEL L51, L65, M31, M37)

本文通过构建监管机构（美国食品药品监督管理局，Food and Drug Administration，简称FDA）与制药企业之间的互动模型，探析了上市后促销活动与药品不良反应（Adverse Drug Reactions）报告之间的关联。由促销驱动的市场扩张虽可提升企业盈利能力，但亦可能引发不规范处方的风险，进而招致针对该企业的监管行动。本文创新性地整合制药促销的商业数据与FDA的监管干预及ADRs报告数据，对药品促销与ADRs报告之间的关联开展实证检验。本研究提供的证据表明，针对部分病症，促销与广告投入的增加会导致ADRs报告量的上升。（JEL分类号：L51、L65、M31、M37）